#### Abstract 7850

#### Comparative Assessment of Sunitinib-associated Adverse Events as Potential Biomarkers of Efficacy in Metastatic Renal Cell Carcinoma (mRCC)

F Donskov,<sup>1</sup> MD Michaelson,<sup>2</sup> I Puzanov,<sup>3</sup> MP Davis,<sup>4</sup> GA Bjarnason,<sup>5</sup> RJ Motzer,<sup>6</sup> X Lin,<sup>7</sup> DP Cohen,<sup>7</sup> R Wiltshire,<sup>8</sup> BI Rini<sup>9</sup>

<sup>1</sup>Aarhus University Hospital, Aarhus, Denmark;
<sup>2</sup>Massachusetts General Hospital Cancer Center, Boston, MA, USA;
<sup>3</sup>Vanderbilt University Medical Center, Nashville, TN, USA;
<sup>4</sup>Cleveland Clinic, Cleveland, OH, USA;
<sup>5</sup>Sunnybrook Odette Cancer Centre, Toronto, Canada;
<sup>6</sup>Memorial Sloan-Kettering Cancer Center, New York, NY, USA;
<sup>7</sup>Pfizer Oncology, La Jolla, CA, USA; <sup>8</sup>Pfizer Oncology, Tadworth, UK;
<sup>9</sup>Cleveland Clinic Taussig Cancer Institute, Cleveland, OH, USA

## **Disclosure**

 Dr. Donskov has reported receiving research funding from Pfizer

## Introduction


- Prior retrospective analyses of pooled data from five clinical mRCC trials have separately identified the following treatmentassociated AEs as potential biomarkers of sunitinib efficacy:
  - hypertension<sup>1\*</sup>

- hand–foot syndrome<sup>2</sup>
- neutropenia<sup>3</sup> thrombocytopenia<sup>3</sup>
- asthenia/fatigue<sup>4</sup>
- AEs were chosen for study if they were common, manageable, readily and systematically measurable, and potentially reflective of intended target inhibition with sunitinib
- We assessed the relative strength and independence of each biomarker in a combined analysis using the same database

\*This efficacy biomarker analysis included three trials, excluding two trials that used continuous daily dosing (CDD), rather than the approved Schedule 4/2


1. Rini BI, et al. *J Natl Cancer Inst* 2011;103:763–773; 2. Michaelson MD, et al. *J Clin Oncol* 2011;29(suppl 7; abstr 320); 3. Donskov F, et al. *Eur J Cancer* 2011;47:S136(abstr 1141); 4. Davis MP, et al. *Eur J Cancer* 2011:47:S135(abstr 1139).

#### Sunitinib-associated Hypertension (HTN) Has Been Associated with Improved Clinical Outcomes




- HTN-associated complications were investigated by expanding the safety analysis with 4,373 patients from an expanded access trial
  - AE rates were similar for patients with and without SBP-defined HTN; however, patients with HTN had somewhat more renal AEs (5% vs. 3%; P=0.013)

#### Sunitinib-associated Hand–foot Syndrome (HFS) Has Been Associated with Improved Clinical Outcomes




#### Sunitinib-associated Myelosuppression Has Been Associated with Improved Clinical Outcomes



- Neutropenia- and thrombocytopenia-related AEs were investigated by expanding the safety analysis with 4,388 patients from an expanded access trial
  - Related AEs were more frequent with neutropenia grade ≥2 and thrombocytopenia grade >1 (P<0.001)</li>

#### Sunitinib-associated Asthenia/Fatigue (A/F) Has Been Associated with Improved Clinical Outcomes



## **Study Designs and Treatments**

- A retrospective analysis with pooled data from 770 mRCC patients who received sunitinib in five clinical trials<sup>1–5</sup>
  - 1st-line (n=494; 64%)
  - 2nd-line (n=276; 36%)
- Oral sunitinib was administered at:
  - 50 mg once daily on Schedule 4/2 (n=544; 71%)
  - 37.5 mg CDD (n=226; 29%)

Motzer RJ, et al. J Clin Oncol 2006;24:16–24;
Motzer RJ, et al. JAMA 2006;295:2516–2524;
Escudier B, et al. J Clin Oncol 2009;27:4068–4075;
Motzer RJ, et al. J Clin Oncol 2009;27:3584–3590;
Barrios CH, et al. Cancer 2012;118:1252–1259.

# **Patient Eligibility**

- Eligibility criteria common to all patients were:
  - age 18 years or older
  - histologically confirmed mRCC
  - adequate organ function
  - presence of measurable disease
  - no known presence of brain metastases
  - Eastern Cooperative Oncology Group performance status (ECOG PS) of 0 or 1

## **Statistical Methods**

- A multivariate Cox proportional-hazard regression model was used to analyze potential independent AE biomarkers
  - repeated using a 12-week landmark to address potential bias from longer treatment (ie, AEs evaluated up to the first 12 weeks)
  - performed separately for patients on Schedule 4/2 and both schedules combined
- The following were used as covariates for prediction of PFS and OS:
  - hypertension (SBP ≥140 mmHg)\*
  - neutropenia and thrombocytopenia (both CTCAE grade >1)
  - any CTCAE grade hand—foot syndrome and asthenia/fatigue
  - dose reduction (adjusted for time on treatment)
  - relative dose intensity for the overall treatment period
  - previously identified prognostic factors<sup>1–3</sup>

\*Results of prior biomarker analyses were similar using DBP-defined hypertension<sup>4</sup>

## **Baseline Patient Characteristics**

Characteristic	2nd-line, Schedule 4/2 Phase II trial <sup>1</sup> (n=63)	2nd-line, Schedule 4/2 Phase II trial <sup>2</sup> (n=106)	1st-line, Schedule 4/2 Phase III trial <sup>3</sup> (n=375)*	1st-line, Schedule CDD Phase II trial <sup>4</sup> (n=119)	2nd-line, Schedule CDD Phase II trial <sup>5</sup> (n=107)
Median (range) age, years	60 (24–87)	56 (32–79)	62 (27–87)	58 <sup>‡</sup> (24–78)	59 (29–80)
ECOG PS, n (%)					
0	34 (54)	58 (55)	231 (62)	63 (53)	61 (57)
1	29 (46)	48 (45)	144 (38)	56 (47)	45 (42)
≥2	0	0	0	0	1 (1)
Prior nephrectomy, n (%)	58 (92)	106 (100)	340 (91)	112 (94)	100 (93)
Prior cytokine therapy, n (%)	63 (100)	106 (100)	0	0	107 (100)
No. of disease sites, n (%)					
1	8 (13)	13 (12)	55 (15)	30 (25)	12 (11)
≥2	55 (87)	93 (88)	320 (85)	87 (73) <sup>¶</sup>	95 (89)

\*The 375 patients cited in the table are those who received sunitinib in this trial

<sup>‡</sup>Mean value presented

<sup>¶</sup>Data missing for two patients

1. Motzer RJ, et al. *J Clin Oncol* 2006;24:16–24; 2. Motzer RJ, et al. *JAMA* 2006;295:2516–2524; 3. Motzer RJ, et al. *J Clin Oncol* 2009;27:3584–3590; 4. Barrios CH, et al. *Cancer* 2012;118:1252–1259; 5. Escudier B, et al. *J Clin Oncol* 2009;27:4068–4075.

#### Final Multivariate Models of Associations Between AEs and Survival for mRCC Patients on Schedule 4/2

		AE at any time point			AE by the 12-week landmark		
AE	Endpoint	HR	95% CI	P value*	HR	95% CI	P value*
Hypertension	PFS	0.29	0.22-0.40	<0.0001	_	-	NS
	OS	0.30	0.24-0.43	<0.0001	0.65	0.51–0.84	0.0008
Hand–foot syndrome	PFS	0.75	0.60–0.94	0.0148	_	-	NS
	OS	0.58	0.44–0.77	0.0001	0.67	0.46–0.98	0.0415
Asthenia/ fatigue	PFS	0.49	0.38–0.64	<0.0001	_	-	NS
	OS	0.72	0.54–0.96	0.0245	_	-	NS
Neutropenia	PFS	_	-	NS	_	-	NS
	OS	_	-	NS	_	-	NS
Thrombocytopenia	PFS	-	_	NS	_	-	NS
	OS	-	-	NS	_	-	NS

NS, not significant \*Wald chi-square test

## Results, cont'd

- Neutropenia and thrombocytopenia were not significant in any of the multivariate analyses, possibly due to a statistically significant correlation of both with hypertension and asthenia/fatigue (r≥0.08; P<0.05, Fisher's exact test), but not with hand–foot syndrome
- Dose reduction, adjusted for time on treatment, was not associated with clinical outcome
- Results were similar with both schedules (Schedule 4/2 and CDD) combined

## Conclusions

- Combined multivariate analyses indicate that hypertension and hand-foot syndrome, and to a lesser degree asthenia/fatigue, may serve as independent on-treatment biomarkers of sunitinib efficacy in mRCC
- The inconsistent landmark results warrant further study, but suggest that hypertension and hand—foot syndrome may be more reliable early predictors of OS than of PFS with sunitinib
- Neutropenia and thrombocytopenia were not significant in the multivariate analyses; however, a statistically significant correlation of both with hypertension and asthenia/fatigue was seen
- Further study into underlying biological mechanisms is warranted
- Providers who observe these AEs are encouraged to continue sunitinib therapy, managing AEs with standard medical treatment with or without dose reduction as clinically indicated

## **Acknowledgments**

- We would like to thank all of the participating patients and their families, as well as the investigators, research nurses, study coordinators, and operations staff
- This study was sponsored by Pfizer Inc
- Medical writing support was provided by Andy Gannon at ACUMED<sup>®</sup> (New York, NY) with funding from Pfizer Inc